glp 1 drugs and cancer Glucagon-like peptide receptor agonists risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research HuMOLYTE | Relief from Chemo
Description
Tirzepatide may decrease circulating BCAAs/BCKAs by encouraging their catabolism in BAT, according to their hypothesis based on these findings
Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Restraints & Challenges: A shortage of numerous glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has occurred, owing to a large increase in demand
Gastrointestinal intolerance, particularly nausea and vomiting, may affect adherence despite their tendency to diminish over time (Liu et al., 2022)
May 2022
